184 related articles for article (PubMed ID: 34233750)
21. Initiation and Receipt of Medication for Opioid Use Disorder Among Adolescents and Young Adults in 4 State Medicaid Programs in 2018: Improving Medicaid Quality Metrics.
Lynch V; Clemans-Cope L
Subst Use Addctn J; 2024 Jul; 45(3):434-445. PubMed ID: 38294428
[TBL] [Abstract][Full Text] [Related]
22. Trends and age-related disparities in opioid use disorder treatment admissions for adolescents and young adults.
Welsh JW; Dennis ML; Funk R; Mataczynski MJ; Godley MD
J Subst Abuse Treat; 2022 Jan; 132():108584. PubMed ID: 34391589
[TBL] [Abstract][Full Text] [Related]
23. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
Grove LR; Rao N; Domino ME
Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
[TBL] [Abstract][Full Text] [Related]
24. Medication Treatment and Health Care Use Among Adolescents With Opioid Use Disorder in Ohio.
Chavez LJ; Bonny AE; Bradley KA; Lapham GT; Cooper J; Miller W; Chisolm DJ
J Adolesc Health; 2020 Jul; 67(1):33-39. PubMed ID: 32276749
[TBL] [Abstract][Full Text] [Related]
25. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
[TBL] [Abstract][Full Text] [Related]
26. Utilization of treatment by Medicaid enrollees with opioid use disorder and co-occurring substance use disorders.
O'Brien P; Henke RM; Schaefer MB; Lin J; Creedon TB
Drug Alcohol Depend; 2020 Dec; 217():108261. PubMed ID: 32979735
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis C Virus Screening among Medicaid-Insured Individuals with Opioid Use Disorder across Substance Use Disorder Treatment Settings.
Choi S; Healy S; Shapoval L; Forthal S; Neighbors CJ
Subst Use Misuse; 2021; 56(2):258-263. PubMed ID: 33345680
[No Abstract] [Full Text] [Related]
28. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder.
Haffajee RL; Lin LA; Bohnert ASB; Goldstick JE
JAMA Netw Open; 2019 Jun; 2(6):e196373. PubMed ID: 31251376
[TBL] [Abstract][Full Text] [Related]
29. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
[No Abstract] [Full Text] [Related]
30. Racial Inequality in Receipt of Medications for Opioid Use Disorder.
Barnett ML; Meara E; Lewinson T; Hardy B; Chyn D; Onsando M; Huskamp HA; Mehrotra A; Morden NE
N Engl J Med; 2023 May; 388(19):1779-1789. PubMed ID: 37163624
[TBL] [Abstract][Full Text] [Related]
31. State- and County-Level Geographic Variation in Opioid Use Disorder, Medication Treatment, and Opioid-Related Overdose Among Medicaid Enrollees.
Lindner SR; Hart K; Manibusan B; McCarty D; McConnell KJ
JAMA Health Forum; 2023 Jun; 4(6):e231574. PubMed ID: 37351873
[TBL] [Abstract][Full Text] [Related]
32. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
Haffajee RL; Andraka-Christou B; Attermann J; Cupito A; Buche J; Beck AJ
Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):69. PubMed ID: 32928272
[TBL] [Abstract][Full Text] [Related]
33. Factors associated with clinician treatment recommendations for patients with a new diagnosis of opioid use disorder.
Lin LA; Powell VD; Macleod C; Bohnert ASB; Lagisetty P
J Subst Abuse Treat; 2022 Oct; 141():108827. PubMed ID: 35863212
[TBL] [Abstract][Full Text] [Related]
34. Characteristics and current clinical practices of opioid treatment programs in the United States.
Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
[TBL] [Abstract][Full Text] [Related]
35. Non-overdose acute care hospitalizations for opioid use disorder among commercially-insured adults: a retrospective cohort study.
Raman SR; Ford CB; Hammill BG; Clark AG; Clifton DC; Jackson GL
Addict Sci Clin Pract; 2023 Jul; 18(1):42. PubMed ID: 37434260
[TBL] [Abstract][Full Text] [Related]
36. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
37. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
[TBL] [Abstract][Full Text] [Related]
38. The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder.
Cole ES; DiDomenico E; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kim JY; Kmiec J; Kelley D; Donohue JM
J Gen Intern Med; 2019 Jun; 34(6):936-943. PubMed ID: 30887440
[TBL] [Abstract][Full Text] [Related]
39. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
Manhapra A; Agbese E; Leslie DL; Rosenheck RA
Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
[TBL] [Abstract][Full Text] [Related]
40. Sex Differences in Opioid Use Disorder Prevalence and Multimorbidity Nationally in the Veterans Health Administration.
Peltier MR; Sofuoglu M; Petrakis IL; Stefanovics E; Rosenheck RA
J Dual Diagn; 2021; 17(2):124-134. PubMed ID: 33982642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
